Dr Reddys unveils Methylprednisolone Sodium Succinate for Injection in US

Methylprednisolone sodium succinate for Injection, USP is an anti-inflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient.

Published On 2022-04-06 06:53 GMT   |   Update On 2022-04-06 06:53 GMT
Advertisement

Hyderabad: Pharma major, Dr. Reddy's Laboratories Ltd., has announced the launch of Methylprednisolone Sodium Succinate for Injection, USP indicated for various conditions including arthritis, blood disorders and severe allergic reactions, in the U.S. market. 

The product is a generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) and has been approved by the U.S. Food and Drug Administration (USFDA).

Advertisement

Dr. Reddy's Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial,125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.

Methylprednisolone sodium succinate for Injection, USP is an anti-inflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient. Methylprednisolone sodium succinate, USP, is the sodium succinate ester of methylprednisolone, and it occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.

Read also: Dr Reddys, Binnopharm ink pact for 2 anti-bacterial brands for Russian region

Methylprednisolone sodium succinate is soluble in water; it may be administered in a small volume of diluent and is well suited for intravenous use in situations where high blood levels of methylprednisolone are required rapidly.

The SOLU-MEDROL brand and generic had U.S. sales of approximately $144 million MAT for the most recent twelve months ending in February 2022 according to IQVIA Health.

SOLU-MEDROL is a trademark of Pharmacia & Upjohn Company LLC

Read also: Dr Reddys, MediCane Health introduce medical cannabis products in Germany

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News